Diabetes & Metabolism Journal

Original Articles

Cardiovascular Risk/Epidemiology
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study: Ye Seul Yang, Nam Hoon Kim, Jong Ha Baek, Seung-Hyun Ko, Jang Won Son, Seung-Hwan Lee, Sang Youl Rhee, Soo-Kyung Kim, Tae Seo Sohn, Ji Eun Jun, In-Kyung Jeong, Chong Hwa Kim, Keeho Song, Eun-Jung Rhee, Junghyun Noh, Kyu Yeon Hur, Committee of Clinical Practice Guidelines, Korean Diabetes Association; Diabetes Metab J. 2024;48(2):279-289. Published online January 26, 2024; DOI: https://doi.org/10.4093/dmj.2023.0225

1,105 View
148 Download
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Recent diabetes management guidelines recommend that sodium-glucose cotransporter 2 inhibitors (SGLT2is) or glucagon-like peptide 1 receptor agonists (GLP-1RAs) with proven cardiovascular benefits should be prioritized for combination therapy in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD). This study was aimed at evaluating SGLT2i or GLP-1RA usage rates and various related factors in patients with T2DM and established CVD.
Methods
We enrolled adults with T2DM aged ≥30 years who were hospitalized due to established CVD from January 2019 to May 2020 at 13 secondary and tertiary hospitals in Korea in this retrospective observational study.
Results
Overall, 2,050 patients were eligible for analysis among 2,107 enrolled patients. The mean patient age, diabetes duration, and glycosylated hemoglobin level were 70.0 years, 12.0 years, and 7.5%, respectively. During the mean follow-up duration of 9.7 months, 25.7% of the patients were prescribed SGLT2is after CVD events. However, only 1.8% were prescribed GLP-1RAs. Compared with SGLT2i non-users, SGLT2i users were more frequently male and obese. Furthermore, they had a shorter diabetes duration but showed worse glycemic control and better renal function at the time of the event. GLP-1RA users had a longer duration of diabetes and worse glycemic control at the time of the event than GLP-1RA non-users.
Conclusion
The SGLT2i or GLP-1RA prescription rates were suboptimal in patients with T2DM and established CVD. Sex, body mass index, diabetes duration, glycemic control, and renal function were associated with the use of these agents.

Citations

Citations to this article as recorded by

Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
Gwanpyo Koh
Diabetes & Metabolism Journal.2024; 48(2): 208. CrossRef

Drug Regimen
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial: Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon; Diabetes Metab J. 2023;47(6):796-807. Published online February 9, 2023; DOI: https://doi.org/10.4093/dmj.2022.0315

40,040 View
572 Download
4 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development. This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with type 2 diabetes mellitus (T2DM) against dapagliflozin.
Methods
In this multicenter, double-blind, randomized, phase 3 study, 200 patients were randomized to receive enavogliflozin 0.3 mg/day (n=101) or dapagliflozin 10 mg/day (n=99) in addition to ongoing metformin therapy for 24 weeks. The primary objective of the study was to prove the non-inferiority of enavogliflozin to dapagliflozin in glycosylated hemoglobin (HbA1c) change at week 24 (non-inferiority margin of 0.35%) (Clinical trial registration number: NCT04634500).
Results
Adjusted mean change of HbA1c at week 24 was –0.80% with enavogliflozin and –0.75% with dapagliflozin (difference, –0.04%; 95% confidence interval, –0.21% to 0.12%). Percentages of patients achieving HbA1c <7.0% were 61% and 62%, respectively. Adjusted mean change of fasting plasma glucose at week 24 was –32.53 and –29.14 mg/dL. An increase in urine glucose-creatinine ratio (60.48 vs. 44.94, P<0.0001) and decrease in homeostasis model assessment of insulin resistance (–1.85 vs. –1.31, P=0.0041) were significantly greater with enavogliflozin than dapagliflozin at week 24. Beneficial effects of enavogliflozin on body weight (–3.77 kg vs. –3.58 kg) and blood pressure (systolic/diastolic, –5.93/–5.41 mm Hg vs. –6.57/–4.26 mm Hg) were comparable with those of dapagliflozin, and both drugs were safe and well-tolerated.
Conclusion
Enavogliflozin added to metformin significantly improved glycemic control in patients with T2DM and was non-inferior to dapagliflozin 10 mg, suggesting enavogliflozin as a viable treatment option for patients with inadequate glycemic control on metformin alone.

Citations

Citations to this article as recorded by

Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park
Cardiovascular Diabetology.2024;[Epub] CrossRef
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes
Sae Im Jeong, Mu Seong Ban, Jun‐Gi Hwang, Min‐Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae‐Yong Chung
Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef
Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis
Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816. CrossRef
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun
The Journal of Korean Diabetes.2023; 24(3): 148. CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin
Sang Youl Rhee
Diabetes & Metabolism Journal.2023; 47(6): 769. CrossRef

Letter

Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2021;45:46-54): Ye Seul Yang, Tae Seo Sohn; Diabetes Metab J. 2021;45(2):277-278. Published online March 25, 2021; DOI: https://doi.org/10.4093/dmj.2021.0028

3,511 View
77 Download

PDF PubReader ePub

Brief Report

Drug/Regimen
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus: Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon; Diabetes Metab J. 2021;45(6):954-959. Published online November 12, 2020; DOI: https://doi.org/10.4093/dmj.2020.0173

55,052 View
367 Download
3 Web of Science
2 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.

Citations

Citations to this article as recorded by

2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
Diabetes & Metabolism Journal.2023; 47(5): 575. CrossRef
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim,
Diabetes & Metabolism Journal.2021; 45(4): 461. CrossRef

Editorial

Smoking as a Target for Prevention of Diabetes: Ye Seul Yang, Tae Seo Sohn; Diabetes Metab J. 2020;44(3):402-404. Published online June 29, 2020; DOI: https://doi.org/10.4093/dmj.2020.0126

4,605 View
67 Download
2 Web of Science
2 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

Association between Smoking Status and the Risk of Hip Fracture in Patients with Type 2 Diabetes: A Nationwide Population-Based Study
Se-Won Lee, Jun-Young Heu, Ju-Yeong Kim, Jinyoung Kim, Kyungdo Han, Hyuk-Sang Kwon
Endocrinology and Metabolism.2023; 38(6): 679. CrossRef
The Global Burden of Type 2 Diabetes Attributable to Tobacco: A Secondary Analysis From the Global Burden of Disease Study 2019
Jianjun Bai, Fang Shi, Yudiyang Ma, Donghui Yang, Chuanhua Yu, Jinhong Cao
Frontiers in Endocrinology.2022;[Epub] CrossRef

Letter

Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9): Tae Seo Sohn; Diabetes Metab J. 2019;43(6):909-910. Published online December 26, 2019; DOI: https://doi.org/10.4093/dmj.2019.0205

3,041 View
51 Download

PDF PubReader

Original Article

Lifestyle
Body Fat Is Related to Sedentary Behavior and Light Physical Activity but Not to Moderate-Vigorous Physical Activity in Type 2 Diabetes Mellitus: Keun Hee An, Kyung Ah Han, Tae Seo Sohn, Ie Byung Park, Hae Jin Kim, Sung Dae Moon, Kyung Wan Min; Diabetes Metab J. 2020;44(2):316-325. Published online November 12, 2019; DOI: https://doi.org/10.4093/dmj.2019.0029

5,472 View
138 Download
9 Web of Science
10 Crossref

Abstract PDF PubReader

Background

Sedentary behavior (SB) has emerged as a new risk factor for cardiovascular accidents. We investigated whether physical activity levels or SB were related to percent body fat (%BF) in type 2 diabetes mellitus (T2DM).

Methods

In this cross sectional study, we measured the duration of SB, light physical activity (LPA), moderate to vigorous physical activity (MVPA), total energy expenditure, and step counts using a wireless activity tracker (Fitbit HR; FB) for 7 days in free-living conditions, along with %BF using a bio impedance analyzer (Inbody; Biospace) in 120 smartphone users with T2DM. Subjects were divided into exercise (Exe, n=68) and non-exercise (nonExe, n=52) groups based on self-reports of whether the recommended exercises (30 min/day, 3 days/week for 3 months) were performed. SBt, LPAt, MVPAt were transformed from SB, LPA, MVPA for normally distributed variables.

Results

Participants were: female, 59.2%; age, 59.3±8.4 years; body mass index, 25.5±3.4 kg/m²; glycosylated hemoglobin (HbA1c), 7.6%±1.2%; %BF, 30.4%±7.1%. They performed SB for 15.7±3.7 hr/day, LPA for 4.4±1.7 hr/day, and MVPA for 0.9±0.8 hr/day. The %BF was related to SBt and LPAt, but not to MVPA after adjustments for age, gender, and HbA1c. VPA was significantly higher in the Exe group than in the nonExe group, but SB, LPA, and moderate physical activity were not different. Predicted %BF was 89.494 to 0.105 (age), −13.047 (gender), −0.507 (HbA1c), −7.655 (LPAt) (F[4, 64]=62.929, P<0.001), with an R² of 0.785 in multiple linear regression analysis.

Conclusion

Reduced body fat in elderly diabetic patients might be associated with reduced inactivity and increased LPA.

Citations

Citations to this article as recorded by

Explanatory variables of objectively measured 24-h movement behaviors in people with prediabetes and type 2 diabetes: A systematic review
Lotte Bogaert, Iris Willems, Patrick Calders, Eveline Dirinck, Manon Kinaupenne, Marga Decraene, Bruno Lapauw, Boyd Strumane, Margot Van Daele, Vera Verbestel, Marieke De Craemer
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(4): 102995. CrossRef
Association between depression, anemia and physical activity using isotemporal substitution analysis
Hee-kyoung Nam, Jungmi Park, Sung-il Cho
BMC Public Health.2023;[Epub] CrossRef
The Impact of Wearable Technologies in Health Research: Scoping Review
Sophie Huhn, Miriam Axt, Hanns-Christian Gunga, Martina Anna Maggioni, Stephen Munga, David Obor, Ali Sié, Valentin Boudo, Aditi Bunker, Rainer Sauerborn, Till Bärnighausen, Sandra Barteit
JMIR mHealth and uHealth.2022; 10(1): e34384. CrossRef
The Correlation of Prediabetes and Type 2 Diabetes With Adiposity in Adults
Juan Sun, Zhen Liu, Zimu Zhang, Ziyang Zeng, Weiming Kang
Frontiers in Nutrition.2022;[Epub] CrossRef
The Physical Activity Assessment of Adults With Type 2 Diabetes Using Accelerometer-Based Cut Points: Scoping Review
Ioana A Moldovan, Alexa Bragg, Anna S Nidhiry, Barbara A De La Cruz, Suzanne E Mitchell
Interactive Journal of Medical Research.2022; 11(2): e34433. CrossRef
Effects of 4 Weeks of a Technique-Specific Protocol with High-Intensity Intervals on General and Specific Physical Fitness in Taekwondo Athletes: An Inter-Individual Analysis
Alex Ojeda-Aravena, Tomás Herrera-Valenzuela, Pablo Valdés-Badilla, Jorge Cancino-López, José Zapata-Bastias, José Manuel García-García
International Journal of Environmental Research and Public Health.2021; 18(7): 3643. CrossRef
Inter-Individual Variability of a High-Intensity Interval Training With Specific Techniques vs. Repeated Sprints Program in Sport-Related Fitness of Taekwondo Athletes
Alex Ojeda-Aravena, Tomás Herrera-Valenzuela, Pablo Valdés-Badilla, Jorge Cancino-López, José Zapata-Bastias, José Manuel García-García
Frontiers in Physiology.2021;[Epub] CrossRef
EFFECT OF SPORTS MEDICINE ON REDUCING BODY FAT PERCENTAGE AND LEAN BODY MASS
Chunyan Fan
Revista Brasileira de Medicina do Esporte.2021; 27(7): 714. CrossRef
Validation of the effectiveness of a digital integrated healthcare platform utilizing an AI-based dietary management solution and a real-time continuous glucose monitoring system for diabetes management: a randomized controlled trial
Sung Woon Park, Gyuri Kim, You-Cheol Hwang, Woo Je Lee, Hyunjin Park, Jae Hyeon Kim
BMC Medical Informatics and Decision Making.2020;[Epub] CrossRef
Brain activity during a working memory task in different postures: an EEG study
Ju-Yeon Jung, Hwi-Young Cho, Chang-Ki Kang
Ergonomics.2020; 63(11): 1359. CrossRef

Letter

Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86): Hannah Seok, Tae Seo Sohn; Diabetes Metab J. 2019;43(4):545-546. Published online August 20, 2019; DOI: https://doi.org/10.4093/dmj.2019.0130

2,816 View
36 Download
1 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

Deciphering the binding behavior and interaction mechanism of apigenin and α-glucosidase based on multi-spectroscopic and molecular simulation studies
Fuqiang Liang, Keyu Meng, Xinran Pu, Yubo Cao, Yumeng Shi, Jiayi Shi
International Journal of Biological Macromolecules.2024; 264: 130535. CrossRef

Original Articles

Severe Hypoglycemia Is a Serious Complication and Becoming an Economic Burden in Diabetes: Won Chul Ha, Su Jin Oh, Ji Hyun Kim, Jung Min Lee, Sang Ah Chang, Tae Seo Sohn, Hyun Shik Son; Diabetes Metab J. 2012;36(4):280-284. Published online August 20, 2012; DOI: https://doi.org/10.4093/dmj.2012.36.4.280

4,425 View
33 Download
36 Crossref

Abstract PDF PubReader

Background

The prevalence of hypoglycemia is increasing due to the growing incidence of diabetes and the latest strict guidelines for glycated hemoglobin (HbA1c) levels under 7%. This study examined the clinical characteristics, causal factors, and medical costs of severely hypoglycemic patients in an emergency room (ER) of Uijeongbu St. Mary's Hospital.

Methods

The study consisted of a retrospective analysis of the characteristics, risk factors, and medical costs of 320 severely hypoglycemic patients with diabetes who presented to an ER of Uijeongbu St. Mary's Hospital from January 1, 2006 to December 31, 2009.

Results

Most hypoglycemic patients (87.5%, 280/320) were over 60 years old with a mean age of 69.5±10.9 years and a mean HbA1c level of 6.95±1.46%. Mean serum glucose as noted in the ER was 37.9±34.5 mg/dL. Renal function was decreased, serum creatinine was 2.0±2.1 mg/dL and estimated glomerular filtration rate (eGFR) was 48.0±33.6 mL/min/1.73 m². In addition, hypoglycemic patients typically were taking sulfonylureas or insulin and a variety of other medications, and had a long history of diabetes.

Conclusion

Severe hypoglycemia is frequent in older diabetic patients, subjects with low HbA1c levels, and nephropathic patients. Therefore, personalized attention is warranted, especially in long-term diabetics with multiple comorbidities who may not have been properly educated or may need re-education for hypoglycemia.

Citations

Citations to this article as recorded by

The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review
Samuel J Westall, Ram Prakash Narayanan, Simon Watmough, Greg Irving, Niall Furlong, Sid McNulty, Sumudu Bujawansa, Kevin Hardy
Clinical Medicine.2022; 22(3): 257. CrossRef
Analysis of recurrent hypoglycemic events
Chenchen Ma, Yongming Qu, Haoda Fu
Journal of Biopharmaceutical Statistics.2021; 31(1): 5. CrossRef
ROLE OF OCTREOTIDE IN MANAGEMENT OF SULPHONYLUREA - INDUCED REFRACTORY HYPOGLYCEMIA : A CASE REPORT
Akshay Kothari, Kiran Shah
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 3. CrossRef
Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach
João P. Ferreira, Francisco Araújo, Jorge Dores, Lèlita Santos, Estevão Pape, Mónica Reis, Árcia Chipepo, Edite Nascimento, Ana Baptista, Vanessa Pires, Carlos Marques, Adriana S. Lages, João Conceição, Pedro A. Laires, João Pelicano-Romano, Sílvia Alão
Diabetes Therapy.2020; 11(10): 2237. CrossRef
The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals
Xiaomeng Yue, Jiuhong Wu, Zhen Ruan, Michael L. Wolden, Lanting Li, Yong Lin
Value in Health Regional Issues.2020; 21: 17. CrossRef
A closer look at the 2019 Beers criteria
Rishabh Sharma, Malika Arora, Ravinder Garg, Parveen Bansal
Drugs & Therapy Perspectives.2020; 36(3): 116. CrossRef
Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal.2020; 44(6): 828. CrossRef
Comparison of clinical pharmacy specialists and usual care in outpatient management of hyperglycemia in Veterans Affairs medical centers
Heather L Ourth, Kwan Hur, Anthony P Morreale, Francesca Cunningham, Bharat Thakkar, Sherrie Aspinall
American Journal of Health-System Pharmacy.2019; 76(1): 26. CrossRef
Cost‐effectiveness of the psycho‐educational blended (group and online) intervention HypoAware compared with usual care for people with Type 1 and insulin‐treated Type 2 diabetes with problematic hypoglycaemia: analyses of a cluster‐randomized controlled
M. de Wit, S. M. P. A. Rondags, M. W. van Tulder, F. J. Snoek, J. E. Bosmans
Diabetic Medicine.2018; 35(2): 214. CrossRef
Dynamin-related protein 1 mediates low glucose-induced endothelial dysfunction in human arterioles
Michael J. Tanner, Jingli Wang, Rong Ying, Tisha B. Suboc, Mobin Malik, Allison Couillard, Amberly Branum, Venkata Puppala, Michael E. Widlansky
American Journal of Physiology-Heart and Circulatory Physiology.2017; 312(3): H515. CrossRef
Hazardous factors besides infection in hypoglycemia
Yu-Jang Su, Yen-Chun Lai, Chia-Jung Liao
Biomedical Reports.2017; 6(4): 480. CrossRef
Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus from Korea
Gyuri Kim, Yong-ho Lee, Mi Hye Han, Eui-Kyung Lee, Chong Hwa Kim, Hyuk Sang Kwon, In Kyung Jeong, Eun Seok Kang, Dae Jung Kim, Massimo Pietropaolo
PLOS ONE.2016; 11(3): e0151282. CrossRef
Costs associated with emergency care and hospitalization for severe hypoglycemia
G. Veronese, G. Marchesini, G. Forlani, S. Saragoni, L. Degli Esposti, E. Centis, A. Fabbri
Nutrition, Metabolism and Cardiovascular Diseases.2016; 26(4): 345. CrossRef
Risk of hospitalization for hypoglycemia among older Korean people with diabetes mellitus
Hyun Min Kim, Jong-Mi Seong, Jaetaek Kim
Medicine.2016; 95(42): e5016. CrossRef
Risk factors of severe hypoglycemia requiring medical assistance and neurological sequelae in patients with diabetes
Ja Young Jeon, Se Ran Kim, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Jung-Dong Lee, Seung Jin Han
Medicine.2016; 95(47): e5365. CrossRef
Effectiveness of HypoAware, a Brief Partly Web-Based Psychoeducational Intervention for Adults With Type 1 and Insulin-Treated Type 2 Diabetes and Problematic Hypoglycemia: A Cluster Randomized Controlled Trial
Stefanie M.P.A. Rondags, Maartje de Wit, Jos W. Twisk, Frank J. Snoek
Diabetes Care.2016; 39(12): 2190. CrossRef
The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients
Pedro Almeida Laires, João Conceição, Francisco Araújo, Jorge Dores, Catarina Silva, Larry Radican, Ana Nogueira
Expert Review of Pharmacoeconomics & Outcomes Research.2016; 16(2): 315. CrossRef
HypoAware: development and pilot study of a brief and partly web‐based psychoeducational group intervention for adults with Type 1 and insulin‐treated Type 2 diabetes and problematic hypoglycaemia
S. M. P. A. Rondags, M. de Wit, F. J. Snoek
Diabetic Medicine.2016; 33(2): 184. CrossRef
Hypoglycemia and Health Costs
Yong-ho Lee, Gyuri Kim, Eun Seok Kang
The Journal of Korean Diabetes.2016; 17(1): 11. CrossRef
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
Jae-Seung Yun, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2015; 30(1): 6. CrossRef
1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
Hannah Seok, Ji Hye Huh, Hyun Min Kim, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha
Diabetes & Metabolism Journal.2015; 39(2): 164. CrossRef
Intensive Individualized Reinforcement Education Is Important for the Prevention of Hypoglycemia in Patients with Type 2 Diabetes
Yun-Mi Yong, Kyung-Mi Shin, Kang-Min Lee, Jae-Young Cho, Sun-Hye Ko, Min-Hyang Yoon, Tae-Won Kim, Jong-Hyun Jeong, Yong-Moon Park, Seung-Hyun Ko, Yu-Bae Ahn
Diabetes & Metabolism Journal.2015; 39(2): 154. CrossRef
Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention
Badieh Jafari, Mary E. Britton
Journal of Pharmacy Practice and Research.2015; 45(4): 459. CrossRef
HypoAware-a brief and partly web-based psycho-educational group intervention for adults with type 1 and insulin-treated type 2 diabetes and problematic hypoglycaemia: design of a cost-effectiveness randomised controlled trial
Stefanie MPA Rondags, Maartje de Wit, Maurits W van Tulder, Michaela Diamant, Frank J. Snoek
BMC Endocrine Disorders.2015;[Epub] CrossRef
Hypoglycemia in Emergency Department
Yu-Jang Su, Chia-Jung Liao
Journal of Acute Disease.2015; 4(1): 59. CrossRef
Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!
Martin J. Abrahamson
Diabetes Care.2015; 38(1): 166. CrossRef
Association Between Hypoglycemia and Fall-Related Events in Type 2 Diabetes Mellitus: Analysis of a U.S. Commercial Database
Sumesh Kachroo, Hugh Kawabata, Susan Colilla, Lizheng Shi, Yingnan Zhao, Jayanti Mukherjee, Uchenna Iloeje, Vivian Fonseca
Journal of Managed Care & Specialty Pharmacy.2015; 21(3): 243. CrossRef
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey, Michelle A. Baron
Journal of Diabetes and its Complications.2014; 28(3): 393. CrossRef
Management of Diabetes Medications for Patients Undergoing Ambulatory Surgery
Mary Ann Vann
Anesthesiology Clinics.2014; 32(2): 329. CrossRef
Principales factores asociados al coste de la diabetes mellitus tipo 2: revisión de la literatura
Silvia Paz, Diego González Segura, Anna Raya Torres, Luis Lizan
Avances en Diabetología.2014; 30(2): 34. CrossRef
Incidence of hypoglycaemia associated with transient loss of consciousness. A retrospective cohort study
A. Lagi, S. Cencetti, F. Lagi
International Journal of Clinical Practice.2014; 68(8): 1029. CrossRef
Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention
Omodele Awoniyi, Rabia Rehman, Samuel Dagogo-Jack
Current Diabetes Reports.2013; 13(5): 669. CrossRef
Diabetes: support for those at risk of malnutrition in the community
Siobhan Hughes
British Journal of Community Nursing.2012; 17(11): 529. CrossRef
Diabetes patients at risk of malnutrition
Siobhan Hughes
Independent Nurse.2012;[Epub] CrossRef
Type 2 diabetes: the evolution of a disease
Harold E Lebovitz
The British Journal of Diabetes & Vascular Disease.2012; 12(6): 290. CrossRef
Severe Hypoglycemia in Patients with Diabetes
Jae Seung Yun, Seung-Hyun Ko
Diabetes & Metabolism Journal.2012; 36(4): 273. CrossRef

Association of Spot Urine Albumin-to-Creatinine Ratio and 24 Hour-Collected Urine Albumin Excretion Rate in Patients with Type 2 Diabetes Mellitus.: Jee In Lee, Hyuk Sang Kwon, Su Jin Oh, Jung Min Lee, Sang Ah Chang, Bong Yun Cha, Hyun Shik Son, Tae Seo Sohn; Korean Diabetes J. 2009;33(4):299-305. Published online August 1, 2009; DOI: https://doi.org/10.4093/kdj.2009.33.4.299

2,671 View
29 Download

Abstract PDF: BACKGROUND
Measuring urine albumin in diabetic patients is an important screening test to identify those individuals at high risk for cardiovascular disease and the progression of kidney disease. Recently, spot urine albumin-to-creatinine ratio (ACR) has replaced 24 hour-collected urine albumin excretion rate (AER) as a screening test for microalbuminuria given its comparative simplicity. The purpose of the current study was to evaluate the degree of correlation between AER and ACR in the normal, microalbuminuric and macroalbuminuric ranges, and to identify the lower limits of ACR for both genders. METHODS: A total of 310 type 2 diabetics admitted to one center were enrolled in the present study. Following the collection of a spot urine sample, urine was collected for 24 hours and albumin content was measured in both specimens. RESULTS: Mean patient age was 60.2 years. A total of 25.4% had microalbuminuria and 15.8% had macroalbuminuria. The data revealed a strongly positive correlation between AER and ACR across all ranges of albuminuria (R = 0.8). The cut-off value of ACR for 30 mg/day of AER by the regression equation was 24 microgram/mg for men, 42 microgram/mg for women and 31.2 microgram/mg for all patients. The diagnostic performance expressed as the area under the curve (AUC) was 0.938 (95% CI, 0.911-0.965) for ACR. ACR revealed a sensitivity of 84% and specificity of 84%, when a cut-off value of 31.2 microgram/mg was employed. CONCLUSION: ACR was highly correlated with AER, particularly in the range of microalbuminuria. The gender combined cut-off value of ACR in type 2 diabetic patients was determined to be 31.2 microg/mg However, additional studies of large outpatient populations, as opposed to the inpatient population used in the present study, are required to confirm the utility of this value.

The Changes of Central Aortic Pulse Wave Analysis in Metabolic Syndrome.: Jee In Lee, Tae Seo Sohn, Hyuk Sang Kwon, Jung Min Lee, Sang Ah Chang, Bong Yun Cha, Hyun Shik Son; Korean Diabetes J. 2008;32(6):522-528. Published online December 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.6.522

2,443 View
18 Download
3 Crossref

Abstract PDF

The metabolic syndrome (MS) has been characterized as a cluster of risk factors that includes dyslipidemia, hypertension, glucose intolerance and central obesity. This syndrome increases the risk of cardiovascular disease. Augmentation index (AIx), a composite of wave reflection form medium-sized muscular arteries is related to the development of coronary artery disease. The aim of this study is to examine the change on central aortic waveforms in subjects between patients with metabolic syndrome and normal subjects. Using the non-invasive technique of pulse wave analysis by applantation tonometry, we investigated central aortic waveforms in 45 patients with MS and 45 matched controls. The MS was defined by NCEP-ATP III criteria. Age did not differ between the two groups. AIx was significantly elevated in patinets with MS compared with controls (21.91 +/- 11.41% vs 18.14 +/- 11.07%; P < 0.01). Subendocardial viability ratio (SEVR) (158.09 +/- 28.69 vs 167.09 +/- 30.06; P < 0.01) was significantly decreased in patients with MS compared with controls. Only the fasting glucose (r = 0.317, P = 0.03) among the components of MS and age (r = 0.424, P = 0.004) had a positive correlation with AIx. AIx increased as the number of MS components increased. These results show that the MS increased systemic arterial stiffness. Age and fasting blood glucose are independent risk factors of arterial stiffness in MS. The individual MS components, except for fasting blood glucose, do not affect arterial stiffness independently. But the clustering of MS components might interact to synergistically affect arterial stiffness.

Citations

Citations to this article as recorded by

Arterial Stiffness by Aerobic Exercise Is Related with Aerobic Capacity, Physical Activity Energy Expenditure and Total Fat but not with Insulin Sensitivity in Obese Female Patients with Type 2 Diabetes
Ji Yeon Jung, Kyung Wan Min, Hee Jung Ahn, Hwi Ryun Kwon, Jae Hyuk Lee, Kang Seo Park, Kyung Ah Han
Diabetes & Metabolism Journal.2014; 38(6): 439. CrossRef
The Changes of the body composition and vascular flexibility According to Pilates mat Exercise during 12 weeks in elderly women
Ji-Eun Jang, Yong-Kwon Yoo, Byung-Hoon Lee
The Journal of the Korea institute of electronic communication sciences.2013; 8(11): 1777. CrossRef
Traditional East Asian Medical Pulse Diagnosis: A Preliminary Physiologic Investigation
Kylie A. O'Brien, Stephen Birch, Estelle Abbas, Paul Movsessian, Michael Hook, Paul A. Komesaroff
The Journal of Alternative and Complementary Medicine.2013; 19(10): 793. CrossRef

The Efficacy of Fixed Dose Rosiglitazone and Metformin Combination Therapy in Poorly Controlled Subjects with Type 2 Diabetes Mellitus.: Tae Seo Sohn, Jee in Lee, In Ju Kim, Kyung Wan Min, Hyun Shik Son; Korean Diabetes J. 2008;32(6):506-512. Published online December 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.6.506

2,074 View
23 Download

Abstract PDF: BACKGROUND
Obese type 2 diabetic subjects are recently increasing in Korea, indicating the importance of insulin resistance rather than insulin secretory defects in the pathophysioloy of type 2 diabetes. The purpose of this study is to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly controlled subjects with type 2 diabetes mellitus. METHODS: 12 type 2 diabetic subjects who had a HbA1c > 11% or fasting plasma glucose > 15 mmol/L were included. After a 2 week screening period, the subjected took the fixed does rosiglitazone/metformin for 24 weeks. The treatment with rosiglitazone/metformin began at week 0 with an initial dose of 4 mg/1000 mg and, unless tolerability issues arose, subjects would be increased to 6 mg/1500 mg at week 4 and at week 8 to the maximum dose of 8 mg/2000 mg. The primary object of this study was to characterize the magnitude of HbA1c reduction from baseline after 24 weeks of rosiglitazone and metformin treatment in poorly controlled type 2 diabetics. RESULTS: The mean age of the subjects was 48.9 +/- 10.6 years old, body mass index was 25.0 +/- 3.5 kg/m2, HbA1c was 12.0 +/- 1.0%, and fasting plasma glucose was 16.3 +/- 3.1 mmol/L. HbA1c was reduced to 7.54 +/- 1.45% and fasting plasma glucose reduced to 7.96 +/- 2.38 mmol/L at week 24. The proportion of HbA1c responder who showed the reduction from baseline of > or = 0.7% or HbA1c < 7% was 11 among 12 subjects (91.7%). 41% of the subjects (5 among 12 subjects) achieved HbA1c level < 7.0% and 75% (9 among 12 subjects) achieved HbA1c level < 8.0%. CONCLUSIONS: In this study, rosiglitazone and metformin combination therapy was effective in glycemic control in poorly controlled subjects with type 2 diabetes mellitus.

Randomized Controlled Trial

The Effect of Rosiglitazone and Metformin Therapy, as an Initial Therapy, in Patients with Type 2 Diabetes Mellitus.: Tae Seo Sohn, Jee In Lee, In Ju Kim, Kyung Wan Min, Hyun Shik Son; Korean Diabetes J. 2008;32(5):445-452. Published online October 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.5.445

2,902 View
25 Download
2 Crossref

Abstract PDF

BACKGROUND
Type 2 diabetes is usually preceded by a long and clinically silent period of increasing insulin resistance. The purpose of this study is to demonstrate that rosiglitazone and metformin fixed-dose combination therapy (RSG/MET) will safely and effectively control glycemia as a first line of oral therapy, better than rosiglitazone (RSG) or metformin (MET) monotherapy in Korean type 2 diabetes patients. METHODS: This study was a 32-week, multicenter, randomized, double-blind study. Twenty-seven type 2 diabetes patients (males 14; females 13) were included and randomly divided into the rosiglitazone, metformin group, or rosiglitazone /metformin combination groups. The primary objective of this study was to determine the change in HbA1c from baseline (week 0) to week 32. The secondary end-points were to determine changes in fasting plasma glucose (FPG) and homeostasis model assessment insulin resistance (HOMA-IR), from baseline to week 32. Other cardiovascular risk markers were also assessed. RESULTS: At week 32, there were significant reductions in HbA1c and FPG, in all three treatment groups. There was no statistical difference in HbA1c among the three groups, but the decrease in FPG in the RSG/MET group was statistically significant compared to the MET group (P < 0.05). RSG/MET significantly reduced HOMA-IR at week 32 compared to baseline, but there was no difference among the three groups. RSG/MET significantly decreased high-sensitive C-reactive protein (hs-CRP) value at week 32, compared to baseline. There were increases in adiponectin from baseline to week 32 in the RSG and RSG/MET groups, and the increase in the RSG/MET group was statistically significant compared to that of the MET group (P < 0.05). At week 32, there was a significant decrease in plasminogen activator inhibitor-1 (PAI-1) in all three treatment groups, but no statistically significant difference among them. The RSG/MET group significantly decreased in terms of urinary albumin-creatinine ratio at week 32, compared to baseline. CONCLUSIONS: In this study, rosiglitazone and metformin combination therapy was effective in glycemic control as an initial therapy, and it improved cardiovascular risk markers in Korean type 2 diabetes patients.

Citations

Citations to this article as recorded by

Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway
Yuyang Liu, Xiangnan Hu, Xuefeng Shan, Ke Chen, Hua Tang
Cancer Cell International.2019;[Epub] CrossRef
Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
Kun Ho Yoon, Jeong Ah Shin, Hyuk Sang Kwon, Seung Hwan Lee, Kyung Wan Min, Yu Bae Ahn, Soon Jib Yoo, Kyu Jeung Ahn, Sung Woo Park, Kwan Woo Lee, Yeon Ah Sung, Tae Sun Park, Min Seon Kim, Yong Ki Kim, Moon Suk Nam, Hye Soon Kim, Ie Byung Park, Jong Suk Par
Diabetes & Metabolism Journal.2011; 35(1): 26. CrossRef

Editorial

Diabetic Nephropathy and Glomerular Filtration Rate.: Tae Seo Sohn; Korean Diabetes J. 2008;32(3):182-184. Published online June 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.3.182

2,095 View
21 Download

Abstract PDF: No abstract available.

Original Article

Clinical Characteristics and Outcomes of Diabetic Ketoacidosis at a Single Institution.: Jee In Lee, Tae Seo Sohn, Sang Ah Chang, Jung Min Lee, Bong Yun Cha, Ho Young Son, Hyun Shik Son; Korean Diabetes J. 2008;32(2):165-170. Published online April 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.2.165

2,265 View
35 Download
5 Crossref

Abstract PDF

AIMS: The aim of this study was to describe the clinical characteristics and outcomes of diabetic ketoacidosis (DKA) in Hospital for past 6 years. METHODS: We reviewed the retrospective medical records of all patients admitted with a diagnosis of DKA from 2000 to 2005 in Uijeongbu St. Mary's Hospital. Clinical characteristics including precipitating factors and hospital mortality were analyzed. RESULTS: Seventy-eight patients (78 episodes) fulfilled criteria for inclusion in this study. Their mean age was 41.89 years. 66 episodes had a prior history of diabetes but DKA was the initial presentation in 12 episodes. 24.4% were on no treatment, 14.1% were using oral hypoglycemic agents and 53.8% were on insulin. Poor glycemic control were the most common precipitating factor (56.4%). There were 3 deaths. CONCLUSION: Our report is similar with past reports of DKA in Korea. but it is different that poor glycemic control is most common precipitating factor and mortality rate are lower than past reports. This observation suggests that many cases of DKA can be prevented by better access to medical care, proper education, and effective communication with a health care provider.

Citations

Citations to this article as recorded by

Clinical and Laboratory Characteristics of Pediatric Diabetic Ketoacidosis: A Single-Center Study
Iee Ho Choi, Min Sun Kim, Pyoung Han Hwang, Dae-Yeol Lee
The Journal of Korean Diabetes.2017; 18(3): 193. CrossRef
Clinical and Biochemical Characteristics of Elderly Patients With Hyperglycemic Emergency State at a Single Institution
Yun Jae Shin, Dae In Kim, Dong Won Lee, Beung Kwan Jeon, Jung Geun Ji, Jung Ah Lim, Young Jung Cho, Hong Woo Nam
Annals of Geriatric Medicine and Research.2016; 20(4): 185. CrossRef
Evaluation of the Clinical Significance of Ketonuria
Hae-Won Jung, Ile-Kyu Park
Laboratory Medicine Online.2012; 2(1): 15. CrossRef
A Case of Severe Diabetic Ketoacidosis in a Child with Type 2 Diabetes
Jaesung Yu, Hyunju Jin, Joontae Ko, Hoseok Kang
Journal of Korean Society of Pediatric Endocrinology.2011; 16(1): 46. CrossRef
Clinical Characteristics of Patients with Hyperglycemic Emergency State Accompanying Rhabdomyolysis
Soo Kyoung Kim, Jong Ha Baek, Kyeong Ju Lee, Jong Ryeal Hahm, Jung Hwa Jung, Hee Jin Kim, Ho-Su Kim, Sungsu Kim, Soon Il Chung, Tae Sik Jung
Endocrinology and Metabolism.2011; 26(4): 317. CrossRef

First
Prev
Page of 2
Next
Last

Search